Kyowa Hakko Stock Price, News & Analysis

Ardelyx, Inc. announced that its partner, Kyowa Kirin, has submitted a New Drug Application (NDA) to the Japanese Ministry of Health for tenapanor, aimed at treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. This submission triggers $35 million in milestone payments for Ardelyx. The NDA is underpinned by data from four Phase 3 trials demonstrating tenapanor's efficacy in lowering serum phosphorus levels. In the U.S., Ardelyx continues to pursue approval for tenapanor, branded as XPHOZAH, with a review scheduled for November 16, 2022.

MEI Pharma (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. have published Phase 1b clinical study results for zandelisib, a PI3Kδ inhibitor, in The Lancet Oncology. The study showed that an intermittent dosing schedule of zandelisib resulted in a lower risk of significant adverse events than a continuous regimen, without sacrificing efficacy. Out of 97 patients evaluated, the intermittent group exhibited a 20% incidence of Grade 3 or worse adverse events compared to 45% in the continuous group. These results support further Phase 2 and Phase 3 studies for zandelisib in patients with B-cell malignancies.

MEI Pharma announced promising data from the zandelisib clinical development program presented at the 2022 European Hematology Association Hybrid Congress. The Phase 2 TIDAL study reported a 70.3% objective response rate and a 35.2% complete response rate in patients with relapsed or refractory follicular lymphoma. Notably, 87.5% of responses occurred within the first two therapy cycles. Adverse events led to a 9.9% discontinuation rate, primarily consisting of Grade 3 AEs. The study aims to continue assessing zandelisib's safety and efficacy as enrollment progresses in additional cohorts.

MEI Pharma and Kyowa Kirin presented data from the ongoing Phase 2 TIDAL study on zandelisib at the ASCO 2022 Annual Meeting. The study showed a 70.3% objective response rate and a 35.2% complete response rate among patients with relapsed or refractory follicular lymphoma. Notably, 87.5% of responses occurred within the first two cycles of therapy. Safety data indicated that 9.9% of patients discontinued for drug-related adverse events, with 83% reporting Grade 3 adverse events primarily in initial treatment cycles. The results support the continued development of zandelisib, particularly in the Phase 3 COASTAL study.

MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. announced the presentation of Phase 2 TIDAL study data on zandelisib at the ASCO 2022 Annual Meeting, scheduled for June 3-7, 2022. The study evaluates the efficacy and safety of zandelisib, a PI3Kδ inhibitor for treating B-cell malignancies. The abstract ID is 7511, with a poster discussion led by Dr. Andrew David Zelenetz on June 4. MEI Pharma focuses on developing innovative cancer therapies, aiming for FDA approvals for its clinical-stage assets.

LUCA Science and Kyowa Kirin have announced a research collaboration to develop innovative treatments for mitochondrial diseases using LUCA's proprietary mitochondrial therapy platform. Mitochondrial diseases, affecting organs with high energy needs, currently have no definitive cures, only symptomatic treatments. This partnership aims to leverage Kyowa Kirin's drug discovery expertise with LUCA's technology to address the unmet medical needs in mitochondrial therapeutics, as highlighted by both companies’ executives.

MEI Pharma (NASDAQ: MEIP) and Kyowa Kirin (Tokyo: 4151) announced that two abstracts regarding zandelisib, a PI3Kδ inhibitor for B-cell malignancies, will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress from June 9-17, 2022. Oral presentation on June 11 will focus on the efficacy and safety of zandelisib in relapsed or refractory follicular lymphoma, while a poster on June 10 will discuss results from a multi-arm Phase 1b study. These presentations may support future FDA marketing approvals.

La Jolla Institute for Immunology and Kyowa Kirin, Inc. have renewed their collaboration through a three-year agreement, enhancing their longstanding partnership. The new funding will increase annual support for research projects, emphasizing human translational potential and faculty recruitment. Kyowa Kirin will have first rights to negotiate licenses for discoveries resulting from the funded projects. This collaboration aims to fuse Kyowa Kirin's drug development capabilities with LJI's immunology expertise to accelerate the introduction of new therapies.

Cumberland Pharmaceuticals (NASDAQ: CPIX) has acquired SANCUSO^® (granisetron transdermal patch) from Kyowa Kirin for $13.5 million, with additional milestone payments and royalties up to 10% on U.S. net sales. SANCUSO is the only FDA-approved patch for preventing chemotherapy-induced nausea and vomiting, with U.S. sales exceeding $14 million in 2020. This acquisition allows Cumberland to enhance its oncology portfolio, addressing the needs of the approximately 500,000 Americans undergoing chemotherapy each year.